Lupin launches generic Tetrabenazine Tablets
21 November 2018 | News
It is indicated for the treatment of chorea associated with Huntington’s disease
Pharma major Lupin has announced the launch of Tetrabenazine Tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC’s Xenazine® tablets.
It is indicated for the treatment of chorea associated with Huntington’s disease.
Xenazine® tablets had annual sales of $153 million in the US (IQVIA MAT September 2018).
For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively.
